Apertura di iTunes Store.Se iTunes non si apre, fai clic sull'icona dell'applicazione iTunes nel Dock o sul desktop di Windows.Progress Indicator
Apertura di iBooks Store in corsoSe iBooks non si apre, clicca sull'app iBooks nel Dock.Progress Indicator

iTunes is the world's easiest way to organize and add to your digital media collection.

Non abbiamo trovato iTunes sul tuo computer. Per scaricare articoli dall'iTunes Store, installa iTunes adesso.

Hai già iTunes? Fai clic su Anche io ho iTunes! per aprirlo.

I Have iTunes Download gratuito
iTunes per Mac+PC

Recombinant Tissue Plasminogen Activator for the Treatment of Acute Ischemic Stroke (Pharmacology Notes)

Baylor University Medical Center Proceedings 2011, July, 24, 3

Questo libro può essere scaricato con iBooks sul tuo Mac o dispositivo iOS e con iTunes sul tuo computer. I libri devono essere letti con iBooks sia su Mac che su dispositivi iOS.


Clinical practice guidelines published by both the American Heart Association and American Stroke Association (AHA/ASA) in 2007, and the American College of Chest Physicians in 2008, recommend the use of the thrombolytic agent recombinant tissue plasminogen activator (rtPA) for the treatment of acute ischemic stroke (AIS) in eligible patients (1, 2). Approved by the US Food and Drug Administration (FDA) in 1996 for treatment of AIS, intravenous rtPA (or alteplase) is the only thrombolytic agent approved for this indication to date (3). Due to the extremely small timeframe in which a patient is eligible to receive rtPA, it is estimated that only 3% to 5% of stroke sufferers reach a hospital in time to be considered for this treatment (4). This small number is discouraging because "the ultimate goal of early reperfusion therapy is to reduce or prevent brain infarction and thereby minimize the long term disability, neurologic impairment, and stroke-related mortality" (2). As stroke is the third most frequent cause of death in the USA, killing 137,000 people each year, mortality reduction could potentially spare the lives of a large number of patients (5). This article briefly reviews the evidence supporting the use of rtPA for AIS and focuses on important new literature that has impacted practice since the publication of the current AIS guidelines. BACKGROUND

Recombinant Tissue Plasminogen Activator for the Treatment of Acute Ischemic Stroke (Pharmacology Notes)
Vedi in iTunes
  • 2,99 €
  • Disponibile su iPhone, iPad, iPod touch e Mac.
  • Categoria: Salute e benessere
  • Pubblicato: 01/07/2011
  • Editore: The Baylor University Medical Center
  • Pagine: 11
  • Lingua: Inglese
  • Requisiti: Per leggere questo libro, devi disporre di un dispositivo iOS con iBooks 1.3.1 o versione successiva e iOS 4.3.3 o versione successiva, oppure di un Mac con iBooks 1.0 o versione successiva e OS X 10.9 o versione successiva.

Valutazioni dei clienti

Non abbiamo ricevuto abbastanza valutazioni per visualizzare una media per quanto riguarda questo libro.